[Polycystic ovary syndrome, metabolic syndrome, cardiovascular risk and the role of insulin sensitizing agents].
The Polycystic Ovary Syndrome (PCOS) affects 6 to 10% of women of childbearing age. Insulin resistance and hyperinsulinemia are present in nearly all PCOS patients and play a central role in the development of both hyperandrogenism and metabolic syndrome (MS). MS occurs in approximately 43% of PCOS patients, raising the cardiovascular risk to up seven fold in these patients. Several serum, functional and structural markers of endothelial dysfunction and subclinical atherosclerosis were described in PCOS patients, even those young and non-obese. However, despite the fact that PCOS adversely affects the cardiovascular profile, long-term studies did not demonstrate a consistent raise in cardiovascular mortality, which seems to be more observed in the post-menopausal period. Recently, oral contraceptives are being substituted for insulin sensitizing agents (metformin and glitazones) in the PCOS treatment, due to their effects on insulin resistance and cardiovascular risk.
Silva
Regina do Carmo
Rdo C
EPM, UNIFESP, São Paulo, SP. rcarmo@osite.com.br
Pardini
Dolores P
DP
Kater
Claudio E
CE
D050197:Atherosclerosis / Q000209:etiology; D002318:Cardiovascular Diseases / Q000209:etiology*; D005260:Female; D006801:Humans; D017588:Hyperandrogenism / Q000209:etiology; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007249:Inflammation; D024821:Metabolic Syndrome / Q000150:complications*; D011085:Polycystic Ovary Syndrome / Q000150:complications* / Q000188:drug therapy; D012307:Risk Factors; D045162:Thiazolidinediones / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones